Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Conference, Trade Show

Compass Therapeutics to Present Preclinical Data on a Novel PD-1/PD-L1 Bispecific Antibody and from its Proprietary Innate Cell Engager Platform at the 2019 SITC Meeting

Compass Therapeutics, a clinical-stage biotechnology company focused on drugging the human immune synapse to treat human diseases, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting, which is being held November 6-10 in National Harbor, MD.

The first poster will show recent data on CTX-8371, a novel bispecific antibody targeting the inhibitory receptor PD-1 and its ligand, PD-L1. CTX-8371 was discovered in an unbiased screen of checkpoint bispecifics using Compass's proprietary StitchMabsTM technology. CTX- 8371 demonstrates significantly increased potency in vitro and in vivo compared to combinations of monoclonals blocking PD-1 and PD-L1. Mechanistic studies of CTX-8371 suggest that the enhanced potency is associated with its unique ability to drive PD-1 downregulation from the surface of effector T cells.

The second poster presentation describes Compass's innate-cell engager platform. Leveraging its common light-chain technology, Compass has developed a series of bispecific antibodies that simultaneously engage tumor associated antigens and the activating receptor NKp30 expressed on NK cells and other innate effector cells to promote potent and highly selective tumor cell killing.

Full details of the presentations are as follows:

Poster title: CTX-8371, a novel bispecific targeting both PD-1 and PD-L1, is more potent than combination anti-PD-1 and PD-L1 therapy and provides enhanced protection from tumors in vivo
Abstract ID: P251
Date & time: Friday, Nov. 8, 7:00 am - 8:00 pm ET
Location: Poster Hall (Prince George AB), Gaylord National Hotel & Convention Center, National Harbor, Md.

Poster title: A novel class of multi-specific antibodies targeting NKp30 on innate immune cells
Abstract ID: P7770
Date & time: Saturday, Nov. 9, 7:00 am - 8:00 pm ET
Location: Poster Hall (Prince George AB), Gaylord National Hotel & Convention Center, National Harbor, Md.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabsTM and common light-chain based multispecific platforms to empirically identify combinations and multispecifics with optimized activity. The company's lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of innate-cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs. The company's offices and labs are based in Kendall Square in Cambridge, Mass.

These press releases may also interest you

at 05:00
At the SNEC 14th (2020) International Photovoltaic Power Generation and Smart Energy Exhibition & Conference, Yingli Solar Reaches Strategic Cooperation with a Number of Important Partners....

at 00:00
Gulf Business Machines (GBM), a leading end-to-end digital solutions provider, offering industry-leading digital infrastructure, digital business solutions, security and services, has been recently recognized as one of the best places to work for in...

8 aoû 2020
General Dynamics announced today that the negotiating teams from Bath Iron Works and the International Association of Machinists and Aerospace Workers (IAM) Local S6 reached agreement last night on mutually acceptable terms to end the ongoing strike...

8 aoû 2020
In a recent video on his YouTube channel, Deadbeat Inc. founder Dan Brock explains how to survive the pandemic by building a recession proof eCommerce business. You'll uncover the kinds of niche markets thriving right now, how to get visitors for...

8 aoû 2020
SID Display Week, the most influential tradeshow for the global display community, presented the first ever virtual show on August 3, 2020. BOE showed a slew of its innovative display technologies and applications such as printing OLED, flexible...

8 aoû 2020
Many drivers are wondering if the minimum car insurance is enough to protect them. The majority of them prefer to buy only the minimum required liability coverage. However, in some cases, the liability coverage will not be enough to pay for the costs...

News published on 24 october 2019 at 08:05 and distributed by: